Imugene reports positive outcomes in novel virus trial against advanced cancers

Clinical stage immuno-oncology company Imugene (ASX: IMU) has obtained positive initial results from a clinical trial investigating its potential treatment of tumours with a unique cancer-killing virus. The phase 1 MAST (metastatic advanced solid tumours)Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute